PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Drug does not significantly reduce risk of death among patients with severe sepsis

2013-03-20
(Press-News.org) Administration of the drug eritoran to patients with severe sepsis and septic shock failed to demonstrate a significant effect on reducing all-cause 28-day mortality or 1-year mortality, compared with placebo, according to a study in the March 20 issue of JAMA.

Severe sepsis, a syndrome of acute infection complicated by organ dysfunction, is caused by a dysregulated systemic inflammatory response. Sepsis can progress to systemic hypotension (septic shock), multiple organ dysfunction, and death. "Lipopolysaccharide (LPS) or endotoxin, the major component of the outer membrane of gram-negative bacteria, is a potent stimulator of the inflammatory response. LPS triggers inflammation in gram-negative sepsis," according to background information in the article. Eritoran, a synthetic analog (a substance that is similar, but not identical, to another) of lipid A, is a potent and specific antagonist of LPS action. In a phase 2 trial, eritoran-treated patients at high risk of death had lower mortality that was not statistically significant.

Steven M. Opal, M.D., of the Alpert Medical School of Brown University, Providence, R.I., and colleagues conducted a phase 3 trial to evaluate the safety and efficacy of eritoran in reducing mortality in patients with severe sepsis. The randomized, multinational trial was conducted in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in September 2011. Patients with severe sepsis (n=1,961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n=1,304 and n=657 patients, respectively. The primary end point for the study was 28-day all-cause mortality. The secondary end points were all-cause mortality at 3, 6, and 12 months after beginning treatment.

The researchers found that treatment with eritoran did not result in significant reductions in the primary study end point of 28-day mortality in the modified intent-to-treat analysis (randomized patients who received at least 1 dose) population; 28.1 percent (366/1,304) of patients in the eritoran group vs. 26.9 percent (177/657) of patients in the placebo group.

There was also no significant difference in the secondary end point of 1-year all-cause mortality: 44.1 percent (290/657) in the eritoran group vs. 43.3 percent (565/1,304) in the placebo group.

Eritoran was well tolerated with comparable numbers of treatment-emergent adverse events (TEAEs) and serious TEAEs between eritoran and placebo groups.

"These findings are in contrast with several preclinical studies and in phase 1 clinical trials in which eritoran terminated lipopolysaccharide-associated molecular and clinical events when administered in adequate doses. Despite these promising early results, no evidence of significant benefit was observed with eritoran in this large phase 3 trial," the authors write. "Eritoran joins a long list of other experimental sepsis treatments that do not improve outcomes in clinical trials in these critically ill patients." ###

(JAMA. 2013;309(11):1154-1162; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Eisai Inc., Woodcliff Lake, N.J., provided financial support for the initial design, study medications and conduct of the study. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.



ELSE PRESS RELEASES FROM THIS DATE:

Heart failure patients with depression have 4 times risk of death

2013-03-20
Heart failure patients who are moderately or severely depressed have four times the risk of dying and double the risk of having to go to the emergency room or be hospitalized compared to those who are not depressed, according to new research reported in Circulation: Heart Failure, an American Heart Association Journal. "Depression is a key driver of healthcare use in heart failure," said Alanna M. Chamberlain, Ph.D., M.P.H., the study's lead author and assistant professor of epidemiology in the Department of Health Sciences Research at the Mayo Clinic in Rochester, Minn. ...

Anxiety, depression identify heart disease patients at increased risk of dying

2013-03-20
Heart disease patients who have anxiety have twice the risk of dying from any cause compared to those without anxiety, according to new research in the Journal of the American Heart Association. Patients with both anxiety and depression have triple the risk of dying, researchers said. "Many studies have linked depression to an increased risk of death in heart disease patients," said Lana Watkins, Ph.D., lead author of the study and an associate professor in Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, N.C. "However, anxiety hasn't received ...

Sexually naïve male mice, fathers respond differently to pups

2013-03-20
Washington, DC — Sexually naïve male mice respond differently to the chemical signals emitted by newborn pups than males that have mated and lived with pregnant females, according to a study published March 20 in The Journal of Neuroscience. The findings may help scientists to better understand the changes that take place in the brains of some mammals during the transition into parenthood. Sex differences in the behaviors mice display toward newborn pups are well documented. While virgin female mice routinely provide parental care to pups upon first encounter, ...

Under the skin, a tiny laboratory

Under the skin, a tiny laboratory
2013-03-20
VIDEO: EPFL scientists have developed a tiny, portable personal blood testing laboratory: a minuscule device implanted just under the skin provides an immediate analysis of substances in the body, and a... Click here for more information. Humans are veritable chemical factories - we manufacture thousands of substances and transport them, via our blood, throughout our bodies. Some of these substances can be used as indicators of our health status. A team of EPFL scientists ...

High potency statins pose significantly higher risk of kidney injury than low potency, say experts

2013-03-20
Research: Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases Editorial: Statins in acute kidney injury: friend or foe? Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalised for acute kidney injury (AKI), compared with those taking low potency statins, a paper published today on bmj.com suggests. The use of statins is often recommended to reduce the risk of cardiovascular disease among high risk patients. However, ...

Mayo Clinic neurologists present research at American Academy of Neurology Annual Meeting

2013-03-20
SAN DIEGO — Mayo Clinic neurology experts will present research findings on Parkinson's disease, Alzheimer's disease, sleep disorders, concussions, multiple sclerosis and more at the American Academy of Neurology annual meeting in San Diego, March 16. They also are available to offer expert comment on other research findings. Mayo studies being presented and their embargo times include: Cognitively normal people with high amyloid levels likelier to develop dementia EMBARGOED until Monday, March 18, 2013, 1:30 p.m. EDT People who aren't showing signs of cognitive ...

New disorder could classify millions of people as mentally ill

2013-03-20
Personal View: The new somatic symptom disorder in DSM-5 risks mislabeling many people as mentally ill Millions of people could be mislabeled as mentally ill when psychiatry's bible of diagnoses is updated in May, warns a senior doctor in this week's BMJ. The next edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) – used around the world to classify mental disorders - will include a new category of somatic symptom disorder. But Allen Frances, Chair of the current (DSM-IV) task force warns that the DSM-5 ...

Studies for approval of new drugs have insufficient patients to evaluate safety

2013-03-20
For medicines intended for chronic use, the number of patients studied before regulatory approval is insufficient to properly evaluate safety and long-term efficacy, requiring the need for new legislation, according to a study by European researchers published in this week's PLOS Medicine. Current European guidelines specify that in order to fully evaluate the safety of medicines being developed for chronic (long-term) treatment of non-life threatening diseases, at least 1000 patients must take the new drug and that 300 and 100 patients must use the drug for 6 and 12 ...

African immunization systems fall short, African experts say

2013-03-20
In Africa, issues of vaccine supply, financing, and sustainability require urgent attention if the Millennium Development Goals are to be achieved, according to African experts writing in this week's PLOS Medicine. Shingai Machingaidze, Charles Wiysonge, and Gregory Hussey from the University of Cape Town in South Africa commend African countries for their progress in immunisation programmes but infectious disease outbreaks, for example, polio and measles outbreaks, as well as high vaccine dropout rates across the region, indicate failures within the immunisation system. ...

For polar bears, it's survival of the fattest

For polar bears, its survival of the fattest
2013-03-20
One of the most southerly populations of polar bears in the world – and the best studied – is struggling to cope with climate-induced changes to sea ice, new research reveals. Based on over 10 years' data the study, published in the British Ecological Society's Journal of Animal Ecology, sheds new light on how sea ice conditions drive polar bears' annual migration on and off the ice. Lead by Dr Seth Cherry of the University of Alberta, the team studied polar bears in western Hudson Bay, where sea ice melts completely each summer and typically re-freezes from late November ...

LAST 30 PRESS RELEASES:

Study finds ending universal free school meals linked to rising student meal debt and stigma

Innovations in organoid engineering: Construction methods, model development, and clinical translation

Rescheduling coca: Aligning global drug policy with science, tradition, and indigenous rights

BIOFAIR roadmap for an integrated biological and environmental data network

SwRI, 8 Rivers patent more cost-effective, efficient power generation system with liquid oxygen storage

A sacred leaf on trial: Scientists urge WHO to support decriminalizing coca

World’s largest superconducting fusion system will use American technology to measure the plasma within

Mount Sinai receives $4.5 million NIH award to launch a pioneering women’s environmental health research training program

Strong grip strength may protect against obesity-related complications

How to double lung cancer screening rates

Researchers ‘zoom’ in for an ultra-magnified peek at shark skin

AI system finds crucial clues for diagnoses in electronic health records

Gut microbiota disruption predicts severe steatosis in MASLD patients

WSU project reduces hospitalizations among home health-care patients

Rain in the Sahara? UIC researchers predict a wetter future for the desert

Solar-powered lights keep sea turtles out of fishing nets

A prototype glucose battery inspired by the body’s metabolism

A triple-threat iron supplement that also improves gut health

TTUHSC researcher awarded CPRIT grant to study type of pediatric bone cancer

New study finds that ALS and MS likely share an environmental cause

Climate change taking toll on teen mental health, study finds

Hanyang University researchers develop novel sensor for continuous endoleak monitoring

Seoul National University of Science and Technology researchers discover breakthrough materials for removing pharmaceuticals from wastewater

Epigenetic “scars”: Unveiling how childhood trauma affects our genes

Where you live may affect your brain health, new study finds 

Frontiers and World Economic Forum unveil top technologies to accelerate global climate and planetary health solutions

‘How drunk do you feel?’: Ozempic, Wegovy may help reduce alcohol use, Virginia Tech researchers find

Divine punishment as an ancient tool for modern sustainability

Hotter does mean wetter

Internal migrants in the U.S. age with fewer disabilities, study finds

[Press-News.org] Drug does not significantly reduce risk of death among patients with severe sepsis